HSD17B3 and prostate adenocarcinoma: Bioinformatics-aided gene expression profiling showed that, compared to HSD17B2 (0.31-fold, p = 0.0092) and SHBG (0.93-fold, p = 0.78) mRNA expression levels, which are downregulated, HSD17B3 (2.96-fold, p = 1.11 × 10−16) and SRD5A1 (1.3-fold, p = 4.02 × 10−5) transcript levels are upregulated in patients with PCa from the TCGA PRAD cohort (n = 497) (Figure 1B).